Cutaneous leishmaniasis (CL) is not a life-threatening condition. However, its treatment can
cause serious adverse effects and may sometimes lead to death. Recently, safer local …

Background The drug of choice for leishmaniasis is pentavalent antimony and different
regimens are under continuous evaluation. The ideal therapy should be simple, effective …

Two mucocutaneous leishmaniasis cases resistant to therapy are reported here. After the
failure of initial therapies (antimony, amphotericin B and/or pentamidine) patients received a …

Fundamentals: American tegumentary leishmaniasis (ATL) treatment remains a challenge,
since most available drugs are injectable and only a small number of comparative …

The efficacy of an antimony regimen at the dose of 20 mg/kg/day for a 3-4-week period is
well established in the treatment of American cutaneous leishmaniasis. Several drug side …

Twenty-three patients from Rio de Janeiro, Brazil-an area of Leishmania (Viannia)
braziliensis transmission-were randomly assigned to receive either a high dose (20 …

The various methods used to treat cutaneous leishmaniasis (CL) have not given consistent
results. The aim of the present study was to compare the efficacy of a solution of meglumine …

Background Treatment of cutaneous leishmaniasis (CL) remains challenging since the
drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease …

We report a case of a 42 year-old female, who came to a leishmaniasis reference center in
Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis lesion in the right forearm …

BACKGROUND-American cutaneous leishmaniasis is a disease with high prevalence and
incidence in Brazil. The Brazilian Central-Western Region currently holds the third largest …